New Phase 3 trial: A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE] — EMD Serono
Why now
Thesis: Lupus long-term extension, incremental data value
Catalyst to watch: LTE safety and efficacy readout
Main risk: Early-stage, regulatory uncertainty
Why it matters
An EMD Serono lupus long-term extension study is incremental pipeline news with no disclosed financial impact.
Details
Sponsor: EMD Serono; Status: Not Yet Recruiting; Conditions: Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE); Interventions: Enpatoran; Enrollment: 404 (estimated); First posted: 2026-09-25; NCT: NCT07840287
Related assets & topics
HealthcareSources
- clinicaltrials · 2026-09-25 12:00 UTC